Well, you can downplay the UK, but the UK and US tend to be very much aligned.
As for coverage, Car-T requires hospitalization and patients can have incredibly bad reactions that can ultimately make it cost up to a million USD or more in coverage here and likely in the UK it is a huge drain on resources. So it is prioritized to the patients who need it most, as there are other treatments that are considered first line treatment, even here.
The UK also has hesitance and will not cover Optune, which they do not see a compelling cost to benefit justification for its use. Optune costs 240,000 per year, and doesn't end, and can add up to 480,000 or more if a patient survives 2 years and then it just keeps going if they are a long-term survivor, which is unlikely, but certainly can happen.
DCVax-L can be given while a patient sits comfortably in their doctor's office. It is easily dispensed with a shot. It has a set cost, and last we knew that might be substantially less than Optune, and of course it's a 2 year regimen generally that they would want to make from a patients tumor and dendritic cells. If a patient recurs, of course, it can be made again, on the new tumor. But for the patients in the clinical trial, they got their one time creation of dosages and they still substantially increased survival and then also the long-tail more than doubled. With combinations, with other drugs that are approved in the UK, Europe and the US, those survival numbers may be substantially improved, and they are educating the immune system to identify cancer and kill it. The benefit is broad for cancer patients, and some with the worst prognosis do best in comparison to their expected outcome otherwise on the current SOC.
There is no comparison.
And I expect if the UK approves, the US will likely approve and vice versa.
Bullish
Market Data 
Markets 
AI
